Sat, Dec 20, 2014, 12:54 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • eastcoasttroll eastcoasttroll Jan 9, 2013 9:54 AM Flag

    Eun K Yang 10/12/12, OPTR star analyst per Yahoo...


    Jefferies maintained a Buy rating on Optimer Pharmaceuticals (NASDAQ: OPTR), a company that focuses on the discovery, development and commercialization of anti-infective products, with one marketed drug for the treatment of diarrhea, DIFICID (fidaxomicin/OPT-80).

    "While preannounced 3Q12 gross Dificid sales of $18.4M (~+2% q/q) are soft, OPTR's new strategy to drive further Dificid growth is reassuring," said analyst Eun K. Yang.

    To address Dificid cost issues and enable patient access, Optimer Pharmaceuticals CEO offered a new strategy, including a 25 percent discount to acute care hospitals, New Technology Add-On Payment, and a Dificid Rx Assist program.

    Jefferies cut its price target on Optimer to $16.00 (from $17.00) to reflect revised U.S. sales and EU royalties.

    This topic is deleted.
12.780.0000(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.